On May 27, 2026, Abbott has received FDA approval for DECNUPAZ (pivekimab sunirine-pvzy), an intravenous therapy, indicating a potential expansion of AbbVie’s pipeline though the commercial potential remains contingent on successful clinical uptake against existing rivals. While the approval itself does not immediately impact fiscal results, the venture solidifies AbbVie's commitment to this novel mechanism of action and positions it to capture value within the evolving therapeutic landscape.